Daxor Corporation (NASDAQ:DXR) Short Interest Up 155.1% in May

Daxor Corporation (NASDAQ:DXR) was the target of a large growth in short interest in the month of May. As of May 15th, there was short interest totaling 9,066 shares, a growth of 155.1% from the April 30th total of 3,554 shares. Based on an average daily volume of 12,397 shares, the days-to-cover ratio is currently 0.7 days. Currently, 0.4% of the company’s shares are sold short.

Wall Street Analyst Weigh In

DXR has been the subject of a number of research reports. Lake Street Capital initiated coverage on Daxor in a report on Wednesday, February 11th. They set a “buy” rating for the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Daxor in a report on Friday, March 27th. One research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, Daxor has an average rating of “Moderate Buy”.

Daxor Stock Performance

Shares of NASDAQ:DXR traded up $0.40 during mid-day trading on Friday, hitting $10.28. 1,671 shares of the company traded hands, compared to its average volume of 7,739. Daxor has a 52-week low of $8.08 and a 52-week high of $14.76. The firm’s 50 day simple moving average is $10.20 and its 200 day simple moving average is $11.86.

Daxor (NASDAQ:DXR) last announced its earnings results on Monday, March 2nd. The company reported ($0.10) EPS for the quarter.

Institutional Investors Weigh In On Daxor

A number of hedge funds have recently bought and sold shares of DXR. Osaic Holdings Inc. acquired a new stake in Daxor during the 2nd quarter valued at approximately $86,000. Nano Cap New Millennium Growth Fund L P acquired a new stake in Daxor during the 4th quarter valued at approximately $184,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new stake in Daxor during the 1st quarter valued at approximately $245,000. Crescent Grove Advisors LLC acquired a new stake in Daxor during the 1st quarter valued at approximately $104,000. Finally, Aristides Capital LLC acquired a new stake in Daxor during the 1st quarter valued at approximately $403,000. Institutional investors and hedge funds own 1.34% of the company’s stock.

Daxor Company Profile

Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.

In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.